Abstract
The use of direct-acting antiviral agents (e.g., telaprevir, boceprevir) has improved response rates in patients with hepatitis C virus (HCV) genotype 1 infections. Substantial number of drug-drug interactions are anticipated with the use of telaprevir, a cytochrome P450 3A and P-glycoprotein substrate and inhibitor. Herein we describe a patient with HCV-associated hepatocellular carcinoma treated simultaneously with a telaprevir-containing regimen and localized chemotherapy (transcatheter arterial chemoembolization) with doxorubicin. No clinically relevant interactions or adverse events developed while on antiviral therapy
Original language | English (US) |
---|---|
Pages (from-to) | 332-335 |
Number of pages | 4 |
Journal | World Journal of Hepatology |
Volume | 5 |
Issue number | 6 |
DOIs | |
State | Published - 2013 |
Keywords
- Cancer
- Hepatitis C virus
- Hepatocellular carcinoma
- Interactions
- Telaprevir
- Transcatheter arterial chemoembolization
ASJC Scopus subject areas
- Hepatology